07.01.2014 • NewsBiosucciniumBiotechnologyDSM

Marcel Lubben Named President of Reverdia

Reverdia has appointed Marcel Lubben as its new president
Reverdia has appointed Marcel Lubben as its new president

Reverdia, a joint venture between DSM and Roquette Frères, has appointed Marcel Lubben as its new president. Lubben replaces General Manager Will van den Tweel, who led the start-up of Reverdia. Van den Tweel drove the joint collaboration between Roquette and DSM on Biosuccinium and was one of the founders of DSM's innovation initiatives into industrial biotechnology.

Lubben joined DSM in 1994. He held positions in Research, Business Development and Marketing & Sales in DSM Pharma Chemicals and DSM Biologics before transitioning into the industrial biotechnology sector. In 2009, he was appointed Managing Director Licensing for DSM and became Managing Director Venturing & Licensing in 2011. In 2012 he became vice president Bio-based Chemicals & Materials, and he served as a member of the Reverdia board from mid-2012 until the end of 2013.

Company

Reverdia

Urmonderbaan 20H
6167 RD Geleen

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.